According to Coherent MI, the global uncomplicated urinary tract infection market size is estimated to be valued at USD 7.2 billion in 2024 and is expected to surpass USD 14.28 billion by 2031, growing at a CAGR of 10.23% from 2024 to 2031.
The uncomplicated urinary tract infection market is primarily driven by the rapidly increasing prevalence of urinary tract infections across the globe. As per the estimates of the World Health Organization (WHO), UTI accounts for over 8.1 million doctor visits each year in the U.S. alone. Urinary tract infection incidences are high amongst women and the geriatric population. Further, increasing use of potent antibiotics to treat uncomplicated UTI is also contributing to market growth.
Request a Sample Copy of the Report @ https://www.coherentmi.com/industry-reports/uncomplicated-urinary-tract-infection-market/request-sample
Market Trends:
Oral antibiotics segment dominates the market: Oral antibiotics such as Trimethoprim/sulfamethoxazole, nitrofurantoin, and fosfomycin account for majority share of the uncomplicated UTI therapeutics market. Ease of administration and better patient compliance of oral drugs compared injectables drives segment growth.
Advent of novel therapeutics: Innovation and development of novel molecular-targeted therapies and combination therapies present lucrative opportunities. For instance, in 2021, Genesys Therapeutics announced positive Phase II data for caviurin, its first-in-class, host-targeting therapeutic candidate for uncomplicated urinary tract infections.
Uncomplicated Urinary Tract Infection Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2024 |
$7.2 billion |
|
Estimated Value by 2031 |
$14.28 billion |
|
Growth Rate |
Poised to grow at a CAGR of 10.23% |
|
Historical Data |
2019–2023 |
|
Forecast Period |
2024–2031 |
|
Forecast Units |
Value (USD Million/Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
By Treatment, By Pathogen Type, By Therapy |
|
Geographies Covered |
North America, Europe, Asia Pacific, and Rest of World |
|
Growth Drivers |
• Increasing Prevalence of uUTI, especially in Sexually Active Women • Rising Antibiotic Resistance, Pushing the Need for Novel Therapies |
|
Restraints & Challenges |
• Lack of Novel Antibiotics, Leading to Limited Treatment Options |
The treatment segment of the uncomplicated uritary tract infection market is expected to be dominated by antibiotics over the forecast period. Antibiotics account for over 70% of the treatment segment currently due to their wide acceptance and effectiveness in treating most uncomplicated urinary tract infections. Some of the commonly used antibiotics include fosfomycin, nitrofurantoin, and trimethoprim-sulfamethoxazole. These antibiotics are generally prescribed as a 3 to 7 day course to fully treat the infection without complications.
Immediate Delivery Available | Buy This Premium Research Report @ https://www.coherentmi.com/industry-reports/uncomplicated-urinary-tract-infection-market/buynow
Based on pathogen type, the Escherichia coli segment holds the largest share currently due to E. coli being the most common cause of uncomplicated urinary tract infections. E. coli accounts for approximately 80-85% of all uncomplicated urinary tract infections globally. The Klebsiella pneumoniae and Proteus mirabilis segments are expected to witness steady growth through 2031 driven by their increasing role in causing antibiotic-resistant infections. However, E. coli is likely to remain the dominant pathogen type over the forecast period.
The oral therapy segment dominates the therapy segment owing to the ease of administration through oral medications. Oral medications account for over 90% of therapies currently as majority of uncomplicated urinary tract infections can be treated with oral antibiotics alone. The IV therapy segment is expected to show higher growth during the forecast period due to the rise of antibiotic-resistant infections requiring in-patient treatment through IV line administration. However, oral therapies are likely to continue dominating the overall therapy segment through 2031.
Key Market Takeaways
The global uncomplicated urinary tract infection market is anticipated to witness a CAGR of 10.23% during the forecast period 2024-2031, driven by the increasing antibiotic resistance among urinary tract infection causing pathogens. On the basis of treatment, the antibiotics segment is expected to hold a dominant position owing to its wide acceptance and effectiveness. Based on pathogen type, Escherichia coli segment is likely to dominate due to E. coli being the most common cause. Regarding therapy, the oral therapies segment is projected to hold the largest share due to ease of administration.
Regionally, North America is expected to hold a dominant position over the forecast period due to advanced healthcare infrastructure and high disease awareness.
Key players operating in the market include GlaxoSmithKline, Iterum Therapeutics, Fimbrion Therapeutics, Janssen Pharmaceuticals, and Immunotek. These players are focused on developing advanced treatment solutions to overcome the rise of antibiotic resistance.
Recent Developments:
In March 2024, GSK stated that it has been advancing its work on antibiotics to combat multidrug-resistant pathogens. One key development involves a first-in-class antibiotic that showed success in treating certain bacterial infections, including urogenital infections caused by resistant pathogens. While this particular antibiotic (gepotidacin) is not specifically designed for E. coli, it showcases GSK’s focus on tackling antibiotic resistance, especially in markets like uUTI.
In July 2023, Fimbrion Therapeutics announced the development of a novel preventive treatment for recurrent uUTIs. This marks a significant milestone in reducing infection recurrence without relying on antibiotics. The company has been working on developing a treatment that targets the bacterial adhesin FimH, a key virulence factor for urinary tract infections, rather than relying on traditional antibiotics. This approach helps reduce the recurrence of infections without contributing to antibiotic resistance. The milestone of identifying a mannose-containing small molecule inhibitor is part of their ongoing collaboration with GSK and other partners, aiming to provide a non-antibiotic, antimicrobial-sparing therapy for UTI prevention.
Ask For Customization @ https://www.coherentmi.com/industry-reports/uncomplicated-urinary-tract-infection-market/request-sample
Uncomplicated Urinary Tract Infection Market Leaders
- GlaxoSmithKline
- Iterum Therapeutics
- Fimbrion Therapeutics
- Janssen Pharmaceuticals
- Inmunotek
Market Segmentation
By Treatment
- Antibiotics
- Vaccines
By Pathogen Type
- Escherichia Coli
- Klebsiella Pneumoniae
- Proteus Mirabilis
By Therapy
- Oral Therapies
- IV Therapies
By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Find Most Trending Related Reports:
The Paraganglioma Market is estimated to be valued at USD 366.2 Mn in 2024 and is expected to reach USD 412.5 Mn by 2031, growing at a compound annual growth rate (CAGR) of 1.7% from 2024 to 2031.
The Parry Romberg syndrome market is estimated to be valued at USD 418.5 Mn in 2024 and is expected to reach USD 750.5 Mn by 2031, growing at a compound annual growth rate (CAGR) of 8.7% from 2024 to 2031.
The pediatric growth hormone deficiency market is estimated to be valued at USD 4.74 Bn in 2024 and is expected to reach USD 6.82 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.3% from 2024 to 2031.
The postherpetic neuralgia market is estimated to be valued at USD 756.1 Mn in 2024 and is expected to reach USD 1,157.5 Mn by 2031, growing at a compound annual growth rate (CAGR) of 6.3% from 2024 to 2031.
About Us:
At CoherentMI, we are a leading global market intelligence company dedicated to providing comprehensive insights, analysis, and strategic solutions to empower businesses and organizations worldwide. Moreover, CoherentMI is a subsidiary of Coherent Market Insights Pvt Ltd., which is a market intelligence and consulting organization that helps businesses in critical business decisions. With our cutting-edge technology and experienced team of industry experts, we deliver actionable intelligence that helps our clients make informed decisions and stay ahead in today's rapidly changing business landscape.
Contact Us:
Mr.
Shah
CoherentMI,
U.S.: +1-650-918-5898
U.K: +44-020-8133-4027
Australia: +61-2-4786-0457
INDIA: +91-848-285-0837
Email: sales@coherentmi.com
Website: https://www.coherentmi.com
